This announcement contains inside
information as stipulated under the UK version of the
Market Abuse Regulation No 596/2014 which is part of English law by
virtue of the European (Withdrawal) Act 2018, as amended. On
publication of this announcement via a regulatory information
service, this information is considered to be in the public
domain.
06 November
2024
EDX Medical Group
plc
AQSE: EDX
("EDX Medical" or
the "Company")
EDX MEDICAL SIGNS EXCLUSIVE PARTNERSHIP
AGREEMENT
TO PROVIDE ADVANCED TESTICULAR CANCER
TEST
CAMBRIDGE,
UK: EDX Medical Group plc, which
develops innovative digital diagnostic products and services
supporting personalised treatments for cancer, heart disease and
infectious diseases, announces today it has signed an
exclusive distribution agreement with mir|detect GmbH
("mir|detect") to distribute its M371 testicular cancer diagnostic
test in the UK and Nordic markets.
The M371-Test is a simple blood test that
enables highly accurate detection of critical biomarkers of
testicular cancer in its early stages, the most common form of
cancer among young men. More than 20,000 new cases are diagnosed
each year in Europe. The test provides a highly reliable and
cost-effective test solution which detects recurrences during the
follow-up monitoring of patients with 100% sensitivity. In
the UK alone, there are 50,000 survivors of testicular cancer who
may benefit from post-diagnosis monitoring.
The agreement between EDX Medical and
mir|detect covers the UK,
Sweden, Finland, Norway and Denmark.
Professor Sir Chris Evans, OBE,
founder of EDX Medical Group plc, commented:
"We are delighted to be partnering with mir|detect to
increase patient's access to this marvellous test which is clearly
outstanding when compared with previous tests for this type of
cancer. This test is an excellent addition to our rapidly growing
portfolio of class-leading diagnostic solutions."
Dr Mike
Hudson, CEO, EDX Medical Group plc, said:
"We are very pleased to be appointed as the exclusive
distributor of the M371-Test in several countries, which is an
excellent fit with our range of diagnostics which enable healthcare
professionals to personalise and optimise treatment decisions for
all patients. EDX Medical expects to continue to work with
mir|detect in future to further refine and develop the test and
associated services."
Dr Nina
Winter, CEO, mir|detect commented: "The
M371-Test provides faster and more reliable diagnosis of testicular
germ cell tumours. It is minimally invasive, patient friendly and
has a very high and reliable detection of recurrence in patients.
We are delighted to have established our new relationship with EDX
Medical."
The Board of directors of EDX Medical
plc accepts responsibility for this announcement.
Contacts:
|
EDX Medical
Group plc
|
|
|
|
Dr Mike Hudson (Chief Executive
Officer)
|
+44 (0)7812 345 301
|
|
|
|
|
|
|
Oberon
Capital
|
|
|
|
Nick Lovering (Corporate
Adviser)
Adam Pollock (Corporate
Broking)
Mike Seabrook (Corporate
Broking)
|
+44 (0)20 3179 5300
|
|
|
|
|
|
|
Media House
International
|
|
|
|
Ramsay Smith
Gary McQueen
|
+44 (0)7788 414856
ramsay@mediahouse.co.uk
+ 44 (0)7834 694609
gary@mediahouse.co.uk
|
|
|
IFC Advisory
(Investor Relations)
Tim Metcalfe
Graham Herring
|
+44 (0) 203 934 6630
|
|
|
|
|
|
Notes for Editors:
About EDX
Medical Group plc
The EDX Medical Group plc is listed on the
Apex Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by
Professor Sir Christopher Evans, OBE, a medical and life
sciences entrepreneur with more than 30 years of experience,
together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic
solutions combining advanced biological and digital technologies,
EDX Medical seeks to cost effectively improve the detection and
characterisation of disease in order to personalise treatment in a
timely fashion. Early disease detection and biologically-based
personal treatment optimisation is considered to be the most
impactful way of reducing deaths and lowering the cost of
healthcare globally.
EDX Medical Group provides doctors,
hospitals and insurers/payers with access to a portfolio of the
best clinical diagnostics products and services. The Company
operates its own facilities in Cambridge and Oxford,
UK, and has strategic product and technology partnerships with
organisations such as Thermo Fisher EMEA Ltd, a world leader
in supplying life sciences solutions and services.
EDX Medical conducts product development,
validation and distribution to ISO 13485 and provides PCR services
accredited to ISO 15189 by the United Kingdom Accreditation
Service (UKAS).
www.edxmedical.com
